CA2401070A1 - Compositions et methodes destinees au diagnostic et a la therapie du mesotheliome malin - Google Patents

Compositions et methodes destinees au diagnostic et a la therapie du mesotheliome malin Download PDF

Info

Publication number
CA2401070A1
CA2401070A1 CA002401070A CA2401070A CA2401070A1 CA 2401070 A1 CA2401070 A1 CA 2401070A1 CA 002401070 A CA002401070 A CA 002401070A CA 2401070 A CA2401070 A CA 2401070A CA 2401070 A1 CA2401070 A1 CA 2401070A1
Authority
CA
Canada
Prior art keywords
seq
peptide
use according
nucleic acid
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002401070A
Other languages
English (en)
Inventor
Martin A. Cheever
Alexander Gaiger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of CA2401070A1 publication Critical patent/CA2401070A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne des compositions et des méthodes destinées au diagnostic et au traitement des cancers associés à l'antigène de la tumeur de Wilms, et en particulier des mésothéliomes. Dans des modes de réalisation particuliers, l'invention concerne de nouvelles méthodes efficaces, des compositions et des kits permettant d'éliciter une réponse immunitaire et une réponse des lymphocytes T aux fragments antigéniques dérivés des polypeptides de l'antigène de la tumeur de Wilms, ainsi que des méthodes d'utilisation de ces compositions dans le diagnostic, la détection, le traitement, le suivi et/ou la prévention du mésothéliome malin de la plèvre chez l'homme.
CA002401070A 2000-02-22 2001-02-22 Compositions et methodes destinees au diagnostic et a la therapie du mesotheliome malin Abandoned CA2401070A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18407000P 2000-02-22 2000-02-22
US60/184,070 2000-02-22
PCT/US2001/005702 WO2001062920A2 (fr) 2000-02-22 2001-02-22 Compositions et methodes destinees au diagnostic et a la therapie du mesotheliome malin

Publications (1)

Publication Number Publication Date
CA2401070A1 true CA2401070A1 (fr) 2001-08-30

Family

ID=22675440

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002401070A Abandoned CA2401070A1 (fr) 2000-02-22 2001-02-22 Compositions et methodes destinees au diagnostic et a la therapie du mesotheliome malin

Country Status (6)

Country Link
EP (1) EP1261711A2 (fr)
JP (1) JP2003524021A (fr)
AU (1) AU2001247220A1 (fr)
CA (1) CA2401070A1 (fr)
NZ (1) NZ521430A (fr)
WO (1) WO2001062920A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2382604C2 (ru) * 2008-02-05 2010-02-27 Государственное образовательное учреждение дополнительного профессионального образования "Уральская государственная медицинская академия дополнительного образования Федерального агентства по здравоохранению и социальному развитию" (ГОУ ДПО УГМАДО Росздрава) Способ определения метастазирования опухоли вильмса

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1038929B (zh) 1998-07-31 2005-05-06 株式会社国际癌症免疫研究所 基於癌抑制基因wt1的产物的癌抗原
US7901693B2 (en) 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7655249B2 (en) 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030235557A1 (en) * 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7329410B1 (en) 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
US7115272B1 (en) 1998-09-30 2006-10-03 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030072767A1 (en) * 1998-09-30 2003-04-17 Alexander Gaiger Compositions and methods for WT1 specific immunotherapy
EP1371664B1 (fr) 2001-03-22 2008-01-09 International Institute of Cancer Immunology, Inc. Peptide modifie wt1
US7553494B2 (en) 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
US8735357B2 (en) 2001-09-28 2014-05-27 International Institute Of Cancer Immunology, Inc. Method of inducing antigen-specific T cells
US20050002951A1 (en) * 2001-09-28 2005-01-06 Haruo Sugiyama Novel method of inducing antigen-specific t cells
DE10254601A1 (de) * 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
US20080070835A1 (en) * 2003-11-05 2008-03-20 International Institute Of Cancer Immunology, Inc Hla-Dr-Binding Antigen Peptide Derived From Wt1
EP2478913A1 (fr) * 2003-12-01 2012-07-25 Sloan-Kettering Institute For Cancer Research Analogues peptidiques synthétiques de liaison à l'antigène histocompatibilité et leurs utilisations
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
CA2626238C (fr) 2005-10-17 2015-10-06 Memorial Sloan Kettering Cancer Center Peptides de liaison wt1 hla de classe ii, compositions et methodes associees comprenant ces peptides
EP1790664A1 (fr) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Anticorps monoclonaux contre claudin-18 pour le traitement du cancer
US9265816B2 (en) 2006-04-10 2016-02-23 Sloan Kettering Institute For Cancer Research Immunogenic WT-1 peptides and methods of use thereof
CA2886621A1 (fr) 2006-12-28 2008-07-10 International Institute Of Cancer Immunology, Inc. Peptide wt1 a restriction hla-a<sp>*</sp>1101 et composition pharmaceutique le contenant
PL2119778T3 (pl) 2007-02-27 2016-04-29 Int Inst Cancer Immunology Inc Sposób aktywacji pomocniczej komórki T oraz kompozycja do zastosowania w tym sposobie
NZ609460A (en) 2010-10-05 2015-07-31 Otsuka Pharma Co Ltd Method for activating helper t cell
CA2861206C (fr) * 2012-01-13 2021-07-06 Richard J. O'reilly Peptides wt-1 immunogenes et leurs procedes d'utilisation
WO2013167153A1 (fr) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Anticorps utiles dans le diagnostic du cancer
CN105073776B (zh) 2012-11-13 2019-04-12 拜恩科技股份公司 用于治疗表达紧密连接蛋白的癌症疾病的制剂
EA201591168A1 (ru) 2012-12-17 2016-05-31 Оцука Фармасьютикал Ко., Лтд. Способ активации хелперной t-клетки
CN110078813B (zh) 2013-01-15 2023-03-28 纪念斯隆凯特林癌症中心 免疫原性wt-1肽和其使用方法
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
KR102045029B1 (ko) * 2013-02-05 2019-11-14 닛토덴코 가부시키가이샤 점막 투여용 ｗｔ1 펩티드 암 백신 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1038929B (zh) * 1998-07-31 2005-05-06 株式会社国际癌症免疫研究所 基於癌抑制基因wt1的产物的癌抗原
PL201881B1 (pl) * 1998-09-30 2009-05-29 Corixa Corp Izolowany polipeptyd składający się z immunogennej części natywnego WT1, zawierająca go kompozycja farmaceutyczna i szczepionka oraz polinukleotyd kodujący ten polipeptyd

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2382604C2 (ru) * 2008-02-05 2010-02-27 Государственное образовательное учреждение дополнительного профессионального образования "Уральская государственная медицинская академия дополнительного образования Федерального агентства по здравоохранению и социальному развитию" (ГОУ ДПО УГМАДО Росздрава) Способ определения метастазирования опухоли вильмса

Also Published As

Publication number Publication date
WO2001062920A3 (fr) 2002-07-18
JP2003524021A (ja) 2003-08-12
WO2001062920A2 (fr) 2001-08-30
NZ521430A (en) 2004-04-30
EP1261711A2 (fr) 2002-12-04
AU2001247220A1 (en) 2001-09-03

Similar Documents

Publication Publication Date Title
JP4130359B2 (ja) Ｗｔ１特異的免疫療法のための組成物および方法
US8071732B2 (en) Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
CA2465303C (fr) Compositions et procedes d&#39;immunotherapie specifique a wt1
AU2002367594B2 (en) Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
NZ521430A (en) Compositions comprising 1-4 antigenic peptide fragments of the Wilms&#39; tumour gene product for treatment or prevention of malignant mesothelioma
US20020193329A1 (en) Compositions and methods for the therapy and diagnosis of Her-2/neu-associated malignancies
HUP0302824A2 (hu) Vakcinakészítmények
US7323181B2 (en) Compositions and methods for WT1 specific immunotherapy
WO2002013847A2 (fr) Methodes diagnostiques et therapeutiques des tumeurs malignes d&#39;origine hematologiques et virales
CA2383615A1 (fr) Procedes de diagnostic et de therapie de malignites hematologiques ou associees aux virus
WO2001064886A2 (fr) Compositions et procedes pour la detection, le diagnostic et la therapie des malignites hematologiques
US20020150588A1 (en) SPAS-1 cancer antigen
US20030082194A1 (en) Compositions and methods for diagnosis and therapy of malignant mesothelioma
CZ20024213A3 (cs) Prostředky a způsoby léčení a diagnostiky rakoviny prsu
US10316072B2 (en) Immune modulator for immunotherapy and vaccine formulation
US20040175739A1 (en) Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US20020058292A1 (en) Ovarian tumor antigen and methods of use therefor
US20020155468A1 (en) Ovarian tumor antigen and methods of use therefor
US7241876B2 (en) Compositions and methods for the therapy and diagnosis of breast cancer
US7704701B2 (en) Diagnosis of prostate cancer with SPAS-1 cancer antigen
US20020064815A1 (en) Ovarian tumor antigen and methods of use therefor
HK1142910A (en) Compositions and methods for wt1 specific immunotherapy

Legal Events

Date Code Title Description
FZDE Discontinued